Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)


Collapse Overview 
Collapse sponsor award id
331550 (UAMS C25129)


Collapse Biography 

Collapse Time 
Collapse start date
2022-08-24

Collapse end date
2023-08-23